AltruBio to Present at Biotech Showcase™ 2023
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the…
Browsing Tag
AltruBio Inc.
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating…
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of…
AltruBio to Present at Biotech Showcase™ 2022
SAN FRANCISCO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the…